These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 8168080

  • 1. Cellular interactions of CRKL, and SH2-SH3 adaptor protein.
    ten Hoeve J, Kaartinen V, Fioretos T, Haataja L, Voncken JW, Heisterkamp N, Groffen J.
    Cancer Res; 1994 May 15; 54(10):2563-7. PubMed ID: 8168080
    [Abstract] [Full Text] [Related]

  • 2. Tyrosine 207 in CRKL is the BCR/ABL phosphorylation site.
    de Jong R, ten Hoeve J, Heisterkamp N, Groffen J.
    Oncogene; 1997 Feb 06; 14(5):507-13. PubMed ID: 9053848
    [Abstract] [Full Text] [Related]

  • 3. C3G is tyrosine-phosphorylated after integrin-mediated cell adhesion in normal but not in Bcr/Abl expressing cells.
    de Jong R, van Wijk A, Heisterkamp N, Groffen J.
    Oncogene; 1998 Nov 26; 17(21):2805-10. PubMed ID: 9840945
    [Abstract] [Full Text] [Related]

  • 4. Tyrosine phosphorylation of murine Crkl.
    de Jong R, Haataja L, Voncken JW, Heisterkamp N, Groffen J.
    Oncogene; 1995 Oct 19; 11(8):1469-74. PubMed ID: 7478571
    [Abstract] [Full Text] [Related]

  • 5. Interaction of Bcr/Abl with C3G, an exchange factor for the small GTPase Rap1, through the adapter protein Crkl.
    Cho YJ, Hemmeryckx B, Groffen J, Heisterkamp N.
    Biochem Biophys Res Commun; 2005 Aug 12; 333(4):1276-83. PubMed ID: 15982636
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of Grb2 and Crkl proteins results in growth inhibition of Philadelphia chromosome positive leukemic cells.
    Tari AM, Arlinghaus R, Lopez-Berestein G.
    Biochem Biophys Res Commun; 1997 Jun 18; 235(2):383-8. PubMed ID: 9199202
    [Abstract] [Full Text] [Related]

  • 7. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.
    Matulonis U, Salgia R, Okuda K, Druker B, Griffin JD.
    Exp Hematol; 1993 Oct 18; 21(11):1460-6. PubMed ID: 8405226
    [Abstract] [Full Text] [Related]

  • 8. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway.
    Sattler M, Salgia R, Okuda K, Uemura N, Durstin MA, Pisick E, Xu G, Li JL, Prasad KV, Griffin JD.
    Oncogene; 1996 Feb 15; 12(4):839-46. PubMed ID: 8632906
    [Abstract] [Full Text] [Related]

  • 9. Characterization of p87C3G, a novel, truncated C3G isoform that is overexpressed in chronic myeloid leukemia and interacts with Bcr-Abl.
    Gutiérrez-Berzal J, Castellano E, Martín-Encabo S, Gutiérrez-Cianca N, Hernández JM, Santos E, Guerrero C.
    Exp Cell Res; 2006 Apr 01; 312(6):938-48. PubMed ID: 16443220
    [Abstract] [Full Text] [Related]

  • 10. Crkl is complexed with tyrosine-phosphorylated Cbl in Ph-positive leukemia.
    de Jong R, ten Hoeve J, Heisterkamp N, Groffen J.
    J Biol Chem; 1995 Sep 15; 270(37):21468-71. PubMed ID: 7545163
    [Abstract] [Full Text] [Related]

  • 11. Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia.
    ten Hoeve J, Arlinghaus RB, Guo JQ, Heisterkamp N, Groffen J.
    Blood; 1994 Sep 15; 84(6):1731-6. PubMed ID: 7521685
    [Abstract] [Full Text] [Related]

  • 12. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
    Jilani I, Kantarjian H, Gorre M, Cortes J, Ottmann O, Bhalla K, Giles FJ, Albitar M.
    Leuk Res; 2008 Apr 15; 32(4):643-9. PubMed ID: 17900686
    [Abstract] [Full Text] [Related]

  • 13. A novel FRET-based biosensor for the measurement of BCR-ABL activity and its response to drugs in living cells.
    Mizutani T, Kondo T, Darmanin S, Tsuda M, Tanaka S, Tobiume M, Asaka M, Ohba Y.
    Clin Cancer Res; 2010 Aug 01; 16(15):3964-75. PubMed ID: 20670950
    [Abstract] [Full Text] [Related]

  • 14. CRKL binding to BCR-ABL and BCR-ABL transformation.
    Kolibaba KS, Bhat A, Heaney C, Oda T, Druker BJ.
    Leuk Lymphoma; 1999 Mar 01; 33(1-2):119-26. PubMed ID: 10194128
    [Abstract] [Full Text] [Related]

  • 15. Subcellular distribution of p210(BCR-ABL) in CML cell lines and primary CD34+ CML cells.
    Patel H, Marley SB, Greener L, Gordon MY.
    Leukemia; 2008 Mar 01; 22(3):559-71. PubMed ID: 18059481
    [Abstract] [Full Text] [Related]

  • 16. p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene.
    Salgia R, Pisick E, Sattler M, Li JL, Uemura N, Wong WK, Burky SA, Hirai H, Chen LB, Griffin JD.
    J Biol Chem; 1996 Oct 11; 271(41):25198-203. PubMed ID: 8810278
    [Abstract] [Full Text] [Related]

  • 17. CRKL links p210BCR/ABL with paxillin in chronic myelogenous leukemia cells.
    Salgia R, Uemura N, Okuda K, Li JL, Pisick E, Sattler M, de Jong R, Druker B, Heisterkamp N, Chen LB.
    J Biol Chem; 1995 Dec 08; 270(49):29145-50. PubMed ID: 7493940
    [Abstract] [Full Text] [Related]

  • 18. The BCR/ABL oncogene alters interaction of the adapter proteins CRKL and CRK with cellular proteins.
    Uemura N, Salgia R, Li JL, Pisick E, Sattler M, Griffin JD.
    Leukemia; 1997 Mar 08; 11(3):376-85. PubMed ID: 9067577
    [Abstract] [Full Text] [Related]

  • 19. Engagement of the CrkL adaptor in interferon alpha signalling in BCR-ABL-expressing cells.
    Grumbach IM, Mayer IA, Uddin S, Lekmine F, Majchrzak B, Yamauchi H, Fujita S, Druker B, Fish EN, Platanias LC.
    Br J Haematol; 2001 Feb 08; 112(2):327-36. PubMed ID: 11167825
    [Abstract] [Full Text] [Related]

  • 20. Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells.
    Nichols GL, Raines MA, Vera JC, Lacomis L, Tempst P, Golde DW.
    Blood; 1994 Nov 01; 84(9):2912-8. PubMed ID: 7524758
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.